BM-MNC Therapy for Compartment Syndrome
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing the safety of using a patient's own stem cells to treat severe leg injuries. It targets patients who have had surgery for serious muscle damage. The stem cells are injected to help heal the muscle.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, if you have controlled diabetes, taking diabetes medication is acceptable.
How does BM-MNC therapy differ from other treatments for compartment syndrome?
BM-MNC therapy involves injecting a patient's own bone marrow cells directly into the muscle, which is different from the standard treatment of fasciotomy that involves cutting the muscle to relieve pressure. This therapy aims to promote tissue regeneration and recovery, offering a potentially less invasive and more regenerative approach.12345
Who Is on the Research Team?
Kenton Gregory, MD
Principal Investigator
Oregon Health and Science University
Are You a Good Fit for This Trial?
Adults aged 18-70 with lower extremity compartment syndrome requiring fasciotomy, able to consent and follow a rehab program for 24 months. Must have negative HIV test, no severe fractures or neurological conditions that affect rehabilitation, and not be on ventilators. Women of childbearing age must use contraception and have a negative pregnancy test.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single dose of autologous BM-MNCs 5-9 days post-injury and fasciotomy, followed by a minimum of 3 months of standard of care physical rehabilitation
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessments of muscle strength, pain, gait, wound healing, and other secondary outcomes
What Are the Treatments Tested in This Trial?
Interventions
- Intramuscular administration of autologous BM-MNCs
Find a Clinic Near You
Who Is Running the Clinical Trial?
Oregon Health and Science University
Lead Sponsor